The PEAT Act of 2026 amends federal health law to change how certain medications are regulated. Specifically, it prohibits the FDA from classifying a medication as a biological product merely because it contains a protein that has no clinical effect on patients. This legislation appears aimed at thyroid medications and similar treatments that may contain inactive protein components but function through other active ingredients. The bill affects pharmaceutical companies and patients who use these medications by potentially changing the regulatory pathway and approval process for such drugs. No specific funding amounts or implementation timelines are included in the bill text.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.